Synonym
B 669; B-669; B669
IUPAC/Chemical Name
2-Phenazinamine, 3-(cyclohexylimino)-3,5-dihydro-N,5-diphenyl-
InChi Key
HEKDHXICKPDCTL-MXNGAVTRSA-N
InChi Code
InChI=1S/C30H28N4/c1-4-12-22(13-5-1)31-26-20-28-30(21-27(26)32-23-14-6-2-7-15-23)34(24-16-8-3-9-17-24)29-19-11-10-18-25(29)33-28/h1,3-5,8-13,16-21,23,31H,2,6-7,14-15H2/b32-27-
SMILES Code
C1(NC2=CC=CC=C2)=CC3=NC4=C(C=CC=C4)N(C5=CC=CC=C5)C3=C/C1=N/C6CCCCC6
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
444.58
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Plass W, Pohlmann A, Yozgatli HP. N-Salicylidenehydrazides as versatile tridentate ligands for dioxovanadium(V) complexes. J Inorg Biochem. 2000 May 30;80(1-2):181-3. PubMed PMID: 10885484.
2: Steel HC, Matlola NM, Anderson R. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J Antimicrob Chemother. 1999 Aug;44(2):209-16. PubMed PMID: 10473227.
3: Van Rensburg CE, Jooné G, Anderson R. Alpha-tocopherol antagonizes the multidrug-resistance-reversal activity of cyclosporin A, verapamil, GF120918, clofazimine and B669. Cancer Lett. 1998 May 15;127(1-2):107-12. PubMed PMID: 9619865.
4: Van Rensburg CE, Anderson R, Jooné G, Myer MS, O'Sullivan JF. Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line. Anticancer Drugs. 1997 Aug;8(7):708-13. PubMed PMID: 9311448.
5: De Bruyn EE, Steel HC, Van Rensburg EJ, Anderson R. The riminophenazines, clofazimine and B669, inhibit potassium transport in gram-positive bacteria by a lysophospholipid-dependent mechanism. J Antimicrob Chemother. 1996 Sep;38(3):349-62. PubMed PMID: 8889712.
6: Myer MS, Van Rensburg CE. Chemosensitizing interactions of clofazimine and B669 with human K562 erythroleukaemia cells with varying levels of expression of P-glycoprotein. Cancer Lett. 1996 Jan 19;99(1):73-8. Erratum in: Cancer Lett 1996 Mar 29;101(2):263. PubMed PMID: 8564932.
7: Wadee AA, Kuschke RH, Dooms TG, Anderson R. The pro-oxidative riminophenazine B669 neutralizes the inhibitory effects of Mycobacterium tuberculosis on phagocyte antimicrobial activity. Int J Immunopharmacol. 1995 Oct;17(10):849-56. PubMed PMID: 8707450.
8: Prinsloo Y, van Rensburg CE, van der Walt R, Anderson R. Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669. Inflamm Res. 1995 Sep;44(9):379-85. PubMed PMID: 8846196.
9: Wadee AA, Kuschke RH, Dooms TG. The inhibitory effects of Mycobacterium tuberculosis on MHC class II expression by monocytes activated with riminophenazines and phagocyte stimulants. Clin Exp Immunol. 1995 Jun;100(3):434-9. PubMed PMID: 7774052; PubMed Central PMCID: PMC1534481.
10: Van Rensburg CE, Anderson R, Myer MS, Jooné GK, O'Sullivan JF. The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line. Cancer Lett. 1994 Sep 30;85(1):59-63. PubMed PMID: 7923103.
11: van Rensburg CE, van Straten A. An in-vitro investigation of the susceptibility of Enterococcus faecalis to clofazimine and B669. J Antimicrob Chemother. 1994 Feb;33(2):356-8. PubMed PMID: 8182023.
12: Anderson R, Smit MJ. Clofazimine and B669 inhibit the proliferative responses and Na+, K(+)-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism. Biochem Pharmacol. 1993 Dec 3;46(11):2029-38. PubMed PMID: 8267651.
13: Krajewska MM, Anderson R. An in vitro comparison of the effects of the prooxidative riminophenazines clofazimine and B669 on neutrophil phospholipase A2 activity and superoxide generation. J Infect Dis. 1993 Apr;167(4):899-904. PubMed PMID: 8383722.
14: Krajewska MM, Anderson R, O'Sullivan JF. Effects of clofazimine analogues and tumor necrosis factor-alpha individually and in combination on human polymorphonuclear leukocyte functions in vitro. Int J Immunopharmacol. 1993 Feb;15(2):99-111. PubMed PMID: 8385654.
15: Van Rensburg CE, Van Staden AM, Anderson R. The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Cancer Res. 1993 Jan 15;53(2):318-23. PubMed PMID: 7678073.
16: Levy L. Activity of four clofazimine analogues against Mycobacterium leprae. Lepr Rev. 1981 Mar;52(1):23-6. PubMed PMID: 7017318.
